159 related articles for article (PubMed ID: 15141426)
1. [Duloxetine and other tricyclic antidepressive agents: pharmacodynamic effects in the lower urinary tract].
Vela Navarrete R; Pérez Martínez FC; Ramírez Pérez del Yerro M; Cabrera Pérez J; González Enguita C
Actas Urol Esp; 2004 Mar; 28(3):252. PubMed ID: 15141426
[No Abstract] [Full Text] [Related]
2. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
Katofiasc MA; Nissen J; Audia JE; Thor KB
Life Sci; 2002 Aug; 71(11):1227-36. PubMed ID: 12106588
[TBL] [Abstract][Full Text] [Related]
3. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat.
Thor KB; Katofiasc MA
J Pharmacol Exp Ther; 1995 Aug; 274(2):1014-24. PubMed ID: 7636716
[TBL] [Abstract][Full Text] [Related]
4. The treatment of urinary incontinence with Duloxetine.
Basu M; Duckett J
J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
[TBL] [Abstract][Full Text] [Related]
5. Effects of Duloxetine on Urethral Continence Reflex and Bladder Activity in Rats with Cerebral Infarction.
Miyazato M; Kitta T; Kaiho Y; Oshiro T; Saito S; Chancellor MB; de Groat WC; Yoshimura N
J Urol; 2015 Sep; 194(3):842-7. PubMed ID: 25804088
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
Jost W; Marsalek P
Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
[TBL] [Abstract][Full Text] [Related]
7. Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats.
Miyazato M; Kaiho Y; Kamo I; Chancellor MB; Sugaya K; de Groat WC; Yoshimura N
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F264-71. PubMed ID: 18480175
[TBL] [Abstract][Full Text] [Related]
8. What do we know about duloxetine's mode of action? Evidence from animals to humans.
Schuessler B
BJOG; 2006 May; 113 Suppl 1():5-9. PubMed ID: 16529563
[TBL] [Abstract][Full Text] [Related]
9. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.
Troelsen KB; Nielsen EØ; Mirza NR
Psychopharmacology (Berl); 2005 Oct; 181(4):741-50. PubMed ID: 16032412
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain.
Gould GG; Javors MA; Frazer A
Biol Psychiatry; 2007 Jan; 61(2):210-5. PubMed ID: 16650830
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
Westanmo AD; Gayken J; Haight R
Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats.
Katoh A; Eigyo M; Ishibashi C; Naitoh Y; Takeuchi M; Ibii N; Ikeda M; Matsushita A
J Pharmacol Exp Ther; 1995 Mar; 272(3):1067-75. PubMed ID: 7891317
[TBL] [Abstract][Full Text] [Related]
14. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
Wong DT; Bymaster FP
Prog Drug Res; 2002; 58():169-222. PubMed ID: 12079200
[TBL] [Abstract][Full Text] [Related]
15. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
J Neurochem; 1997 Dec; 69(6):2616-9. PubMed ID: 9375697
[TBL] [Abstract][Full Text] [Related]
16. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.
Zinner NR
Expert Opin Investig Drugs; 2003 Sep; 12(9):1559-66. PubMed ID: 12943499
[TBL] [Abstract][Full Text] [Related]
18. Designing a new generation of antidepressant drugs.
Pinder RM
Acta Psychiatr Scand Suppl; 1997; 391():7-13. PubMed ID: 9265946
[TBL] [Abstract][Full Text] [Related]
19. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
Bymaster FP; Lee TC; Knadler MP; Detke MJ; Iyengar S
Curr Pharm Des; 2005; 11(12):1475-93. PubMed ID: 15892657
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine: in stress urinary incontinence.
McCormack PL; Keating GM
Drugs; 2004; 64(22):2567-73; discussion 2574-5. PubMed ID: 15516154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
